Examining the links between COVID-19 seropositivity, metabolic syndrome and depressive symptoms: evidence from ENSANUT 2021–2022
BJPsych International · 29.06.2026 · 1-10
DOI: 10.1192/bji.2026.10116 ↗Kurz gefasst
Fachartikel in der Zeitschrift BJPsych International, online erschienen am 29.06.2026. Verfasst von Reinhard Janssen-Aguilar und 6 weiteren Autor:innen. Die Arbeit nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Themen: Depression
Abstract (Originalsprache)
Background
The COVID-19 pandemic has affected mental health, with a particular impact on depressive symptoms. Metabolic syndrome is also linked to depression, but their combined effects remain unclear.
Aims
To examine the independent and combined effects of COVID-19 seropositivity and metabolic syndrome on depressive symptoms, considering demographic and health-related factors.
Method
A cross-sectional analysis was conducted using 2021–2022 Encuesta Nacional de Salud y Nutrición data. Depressive symptoms were assessed with the Center for Epidemiological Studies Depression Scale (CESD-7), including subscales for positive affect, negative affect and somatic symptoms. COVID-19 seropositivity was determined through seroprevalence data, and metabolic syndrome was defined using Adult Treatment Panel III criteria. Logistic and linear regression models evaluated associations between COVID-19 seropositivity, metabolic syndrome and depressive symptoms, adjusting for demographic and health factors.
Results
Among 10 890 adults, 3312 (30.4%) had depressive symptoms. COVID-19 seropositivity ( n = 7790, 71.7%) was associated with higher odds of depressive symptoms (odds ratio 1.22, 95% CI 1.08–1.38) and increased CESD-7 scores (coefficient 0.39, 95% CI 0.19–0.58), particularly negative affect (coefficient 0.16, 95% CI 0.05–0.27) and somatic symptoms (coefficient 0.23, 95% CI 0.12–0.34). Metabolic syndrome was associated with depressive symptoms (odds ratio 1.17, 95% CI 1.02–1.33), mainly through negative affect (coefficient 0.27, 95% CI 0.12–0.41). No significant interaction was found between COVID-19 seropositivity and metabolic syndrome.
Conclusions
COVID-19 seropositivity and metabolic syndrome independently increase depression risk, highlighting the need for integrated mental and metabolic health screening.
Zitieren
APA
Janssen-Aguilar, R., Lin, Q., Meshkat, S., Al-Shamali, H., Lou, W., Mendez-Dominguez, N., & Bhat, V. (2026). Examining the links between COVID-19 seropositivity, metabolic syndrome and depressive symptoms: evidence from ENSANUT 2021–2022. BJPsych International, 1-10. https://doi.org/10.1192/bji.2026.10116
Vancouver
Janssen-Aguilar R, Lin Q, Meshkat S, Al-Shamali H, Lou W, Mendez-Dominguez N, et al. Examining the links between COVID-19 seropositivity, metabolic syndrome and depressive symptoms: evidence from ENSANUT 2021–2022. BJPsych International. 2026:1-10. doi:10.1192/bji.2026.10116
BibTeX
@article{JanssenAguilar2026,
author = {Janssen-Aguilar, Reinhard and Lin, Qiaowei and Meshkat, Shakila and Al-Shamali, Huda and Lou, Wendy and Mendez-Dominguez, Nina and Bhat, Venkat},
title = {Examining the links between COVID-19 seropositivity, metabolic syndrome and depressive symptoms: evidence from ENSANUT 2021–2022},
journal = {BJPsych International},
year = {2026},
pages = {1--10},
doi = {10.1192/bji.2026.10116}
}
EUVIMED